Effectiveness and safety of home-visiting chemotherapy for advanced cancer patients with difficulty receiving hospital-based chemotherapy

Effectiveness and safety of home-visiting chemotherapy in patients with unresectable or recurrent cancer and difficulty visiting hospitals: a single-center retrospective observational study (INDEPENDENCE Study) - INDEPENDENCE Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060098

Enrollment

142

Registered

2025-12-16

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable advanced cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Age 20 years or older at the start of treatment. 2.Diagnosis of malignancy based on histology, cytology, or imaging studies. 3.Clinical diagnosis of unresectable advanced cancer. 4.Difficulty in attending hospital-based chemotherapy, with prior clinical decision for palliative care or inability to receive outpatient chemotherapy. 5.First home-visit medical care at the study institution between July 1, 2023 and March 31, 2025.

Exclusion criteria

Exclusion criteria: 1.Patients expressing refusal to participate through the opt-out process. 2.Patients considered inappropriate for the study by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Objective response rate, disease control rate, and adverse events	—

Countries

Japan

Contacts

Public ContactNobuhiro Tsuruta

Tendai Medical Corporation, Tsuruta Clinic Department of Medical Oncology

ntsuruta1102@gmail.com092-791-7891

Outcome results